Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
  • A01N25/10—Macromolecular compounds
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
  • A01N47/40—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides
  • A01N47/42—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having a double or triple bond to nitrogen, e.g. cyanates, cyanamides containing —N=CX2 groups, e.g. isothiourea
  • A01N47/44—Guanidine; Derivatives thereof
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
  • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
  • C08K5/00—Use of organic ingredients
  • C08K5/16—Nitrogen-containing compounds
  • C08K5/29—Compounds containing one or more carbon-to-nitrogen double bonds
  • C08K5/31—Guanidine; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L101/00—Compositions of unspecified macromolecular compounds
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to antiviral agent compositions. More specifically, the present invention relates to an antiviral agent composition with excellent antiviral properties and uses thereof.
• This application claims priority to Japanese Patent Application No. 2022-32673 filed on March 3, 2022, the contents of which are incorporated herein.
• Viruses that adversely affect humans, animals or plants e.g. coronaviruses (SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, etc.), type B Hepatitis virus, hepatitis C virus, hepatitis E virus, rabies virus, Ebola virus, AIDS virus, norovirus, poliovirus, rotavirus, Lassa fever virus, AIDS virus, West Nile virus, dengue fever virus, Japanese encephalitis virus, bird flu
• antiviral agents for preventing infection with viruses, human influenza virus, smallpox virus, herpes virus, and the like.
• US Pat. No. 5,900,000 discloses an anti-infective agent containing polyhexamethylene biguanide with an average molecular weight of 2,900-15,000.
• Patent Document 2 discloses a potash characterized by containing 0.05 to 0.5 wt% of a polyhexamethylene guanidine compound and 40 to 95 wt% of a lower alcohol or a mixture thereof, and having a pH in the range of 6 to 9. Compositions with virus-inactivating effects are disclosed.
• Non-Patent Document 4 teaches that among guanidine derivatives introduced with various substituents, only acyl derivatives exhibit antipoliovirus effects, and that the antipoliovirus effects of guanidine are structure-specific.
• Patent Document 5 discloses a method for treating tumor diseases and autoimmune diseases containing salts of guanidine derivatives such as undecylideneaminoguanidine acetate, undecylideneaminoguanidine lactate, undecylideneaminoguanidine enanthate and undecylideneaminoguanidine pelargonate. , discloses pharmaceutical preparations for the treatment of cardio-circulatory, infectious or viral diseases.
• Non-Patent Document 1 teaches guanidine salts and surfactants as virus inactivating agents.
• Non-Patent Document 2 discloses that urea and guanidine hydrochloride, which are known as protein denaturants, have a virus inactivating effect.
• Non-Patent Document 3 discloses a SARS-CoV-2 inactivation reagent containing guanidine thiocyanate as a main component.
• Patent Document 6 discloses 9-(2-hydroxyethoxymethyl)guanidine as an antiviral active agent.
• An object of the present invention is to provide an antiviral agent composition with excellent antiviral properties and uses thereof.
• An antiviral agent composition containing at least one selected from iminoctadine and salts thereof.
• a resin composition comprising the antiviral agent composition of [1] and a resin.
• a molded article containing the resin composition according to [2].
• the antiviral agent composition of the present invention exhibits excellent antiviral properties.
• a composition containing zinc pyrithione or polyhexamethylene biguanide and a resin has very low antiviral properties, but the resin composition, coating composition, adhesive composition or coating composition of the present invention exhibits good antiviral properties. have sex.
• the laminate of the present invention exhibits good antiviral properties.
• the molded article of the present invention has almost no effect on antiviral properties due to heat during molding, and exhibits good antiviral properties even in the shape of lumps, films, strands, filaments, fibers, and the like.
• the antiviral agent composition of the present invention contains at least one selected from iminoctadine and salts thereof (hereinafter sometimes referred to as iminoctadine compound).
• iminoctadine compound is also denoted as 1,1′-[iminodi(octamethylene)]diguanidine.
• iminoctadine salts used in the present invention include iminoctadine hydrochloride, iminoctadine albesilate, and iminoctadine acetate. Of these, iminoctadine albesilate or iminoctadine acetate are preferred.
• Iminoctazine acetate is also referred to as 1,1'-iminiodi(octamethylene)diguanidinium triacetate and is generally represented by the following structural formula.
• the amount of the iminoctadine compound contained in the antiviral agent composition of the present invention can be appropriately set according to the application. parts, more preferably 0.0005 to 75 parts by mass, still more preferably 0.0005 to 40 parts by mass, and particularly preferably 0.001 to 40 parts by mass.
• the antiviral agent composition of the present invention may contain a solvent.
• the solvent is preferably one capable of dispersing or dissolving the iminoctadine compound.
• Specific examples of solvents include water; ethylene glycol mono-n-butyl ether, diethylene glycol monobutyl ether, triethylene glycol monomethyl ether, triethylene glycol monobutyl ether, 2-ethylhexyl glycol, tripropylene glycol monomethyl ether, diethylene glycol monohexyl ether, Glycol ether solvents such as dipropylene glycol monomethyl ether and dipropylene glycol monobutyl ether; Organic acids such as formic acid, acetic acid, lactic acid, oxalic acid, citric acid, and benzoic acid; Methanol, ethanol, isopropyl alcohol, isobutyl alcohol, n- alcohols such as butanol; amines such as ethanolamine, dimethylamine and pyridine; amides such as di
• Hydrocarbons Halogenated hydrocarbons such as dichloromethane, carbon tetrachloride, chloroform, and chilichloroethylene; Acetonitrile; Mineral oil, synthetic hydrocarbon oil, synthetic ester oil, natural fat, natural fat derivative, ether oil, silicon oil, fluorine Oil etc. can be mentioned. These solvents can be used singly or in combination of two or more.
• the amount of the solvent contained in the antiviral agent composition of the present invention can be appropriately set according to the application. It is preferably 10 to 90 parts by mass, more preferably 30 to 90 parts by mass.
• the antiviral agent composition of the present invention can further contain components having antimicrobial properties other than the iminoctadine compound.
• components having antimicrobial properties include antibacterial components, bactericidal components, antiviral components, antifungal components, antiseptic components, antialgal components, and the like. These can be used individually by 1 type or in combination of 2 or more types.
• the antiviral agent composition of the present invention can further contain other ingredients depending on its purpose and application.
• Other ingredients include flame retardants, heat stabilizers, antioxidants, lubricants, antistatic agents, UV absorbers, colorants, dyes/pigments, release agents, heat shields, dispersants, and surfactants. . These can be used individually by 1 type or in combination of 2 or more types.
• the antiviral agent composition of the present invention can be formulated according to its purpose and application.
• Formulations of formulations include, for example, water suspensions, water emulsions, emulsions, liquids containing oils, pastes, powders, granules, microcapsules and the like.
• the antiviral agent composition of the present invention may be molded or granulated by known methods. Examples of molding or granulation methods include extrusion molding or extrusion granulation, stirring granulation, fluid bed granulation, tumbling granulation, spray granulation, compression granulation, and tableting.
• the liquid antiviral agent composition of the present invention can be added, mixed, applied, sprayed, impregnated, etc. with other materials.
• the solid antiviral agent composition of the present invention can be added, mixed, dispersed, adhered, etc. to other materials. By doing so, antiviral properties can be imparted to other materials.
• the antiviral agent composition of the present invention exhibits viral proliferation-suppressing and viral-killing effects. As a result, viral infection to humans, animals or plants can be prevented.
• viruses targeted by the antiviral agent composition of the present invention include Lassa fever virus, AIDS virus, West Nile virus, dengue fever virus, Japanese encephalitis virus, avian influenza virus, human influenza virus, smallpox virus, and herpes virus.
• papillomavirus Sindbis virus, coronavirus, SARS virus, norovirus, adenovirus, hepatitis B virus, Marburg virus, measles virus, rabies virus, poliovirus, rhinovirus, hepatitis A virus, rotavirus, hepatitis C Virus, Tobacco ring spot virus, Tobacco stem virus, Tobacco mosaic virus, Potato virus, Cucumber mosaic virus, Beet necrotic yellow vein virus, Capsicum mild mottle virus, Kidney bean mosaic virus, Kidney bean yellow mosaic virus, Peanut stunt Viruses, bacteriophages and the like can be mentioned.
• the resin composition of the present invention contains the antiviral agent composition of the present invention and a resin.
• the amount of the iminoctazine compound contained in the resin composition of the present invention can be appropriately set according to the application. is 0.0005 to 40 parts by mass, more preferably 0.001 to 20 parts by mass, and particularly preferably 0.001 to 5 parts by mass.
• the resin can be appropriately selected according to the application of the resin composition, the required performance, etc.
• resin is a resin in a broad sense, and includes elastomers, rubbers, etc., in addition to resins in a narrow sense.
• the resin in the present invention may be a thermoplastic resin, a thermosetting resin, or a photocurable resin.
• thermoplastic resins examples include styrene resins, acrylic resins, vinyl acetate resins, acrylonitrile copolymers, polyphenylene oxide resins, polysulfone resins, polyethersulfones, polyarylates, polyetherimides, polyamideimides, polyimides, and polymethacrylic acid.
• Thermosetting resins are those that are hardened by the progress of a polymerization reaction or a cross-linking reaction when heated.
• thermosetting resins include phenol resins, epoxy resins, melamine resins, urea resins, unsaturated polyester resins, alkyd resins, polyurethanes, thermosetting polyimides, and diallyl phthalate resins.
• the thermosetting resin may be a thermoplastic resin mixed with a vulcanizing agent, a curing agent, or a cross-linking agent.
• a photocurable resin is a resin that is cured by a polymerization reaction or a cross-linking reaction when irradiated with light such as ultraviolet rays.
• a desired monomer or oligomer is blended with a photoinitiator such as a photoradical generator, photocation generator, photoacid generator, or photobase generator.
• Monomers or oligomers that can be used in the photocurable resin are not particularly limited, and include (meth)acrylate monomers, (meth)acrylate oligomers, bisphenol A diglycidyl ether, hydrogenated bisphenol A diglycidyl ether, bisphenol F diglycidyl ether, cyclohexane di Methanol diglycidyl ether 3,4-epoxycyclohexylmethyl-3′,4′-epoxycyclohexanecarboxylate, 1,2-epoxy-4-(2-oxiranyl) of 2,2-bis(hydroxymethyl)-1-butanol Cyclohexane adducts; Oxetane compounds such as xylylene bisoxetane and 3-ethyl-3-hydroxymethyloxetane; Vinyl ether monomers such as cyclohexanedimethanol divinyl ether, 2-ethylhexyl vinyl ether, cyclohexanedimethanol monovin
• resins include silicone, acrylic silicone, modified silicone, lacquer, glue, petroleum resin, and hydrogenated petroleum resin; starches such as rice, wheat, corn, potato, sweet potato, tapioca, and other natural products, or those made from and biodegradable plastics.
• the amount of the resin contained in the resin composition of the present invention can be appropriately set according to the application. 95 parts by mass, more preferably 50 to 90 parts by mass.
• the resin composition of the present invention is not particularly limited by the manufacturing method.
• it can be obtained by mixing an iminoctadine compound or the antiviral agent composition of the present invention, a resin, and, if necessary, a known resin additive by a known method.
• Additives for resins include antioxidants, heat deterioration inhibitors, light stabilizers, lubricants, release agents, polymer processing aids, antistatic agents, flame retardants, dyes and pigments, light diffusing agents, organic pigments, gloss Erasing agents, impact modifiers, phosphors, fillers, preservatives, anti-algae agents, pigment dispersants, plasticizers, drying accelerators, surfactants, anti-foaming agents, anti-skinning agents, low-temperature film-forming agents , film-forming aids, thickeners, leveling agents, dispersants, anti-settling agents, curing agents, curing aids, anti-freezing agents, and the like.
• a resin, and known additives for resins that are optionally used can be carried out using, for example, a kneader-ruder, a single-screw or multi-screw extruder, a mixing roll, and a Banbury mixer. It can be carried out using a known mixing device or kneading device such as.
• the liquid thermosetting resin or photocurable resin before curing can be mixed with the iminoctadine compound or the antiviral agent composition of the present invention and known resin additives used as necessary by tank blending.
• the resin composition of the present invention can be made into a desired shape by a known molding method. Further, the liquid resin composition of the present invention can be added, applied, sprayed, or impregnated into other materials. The solid resin composition of the present invention can be mixed and adhered to other materials.
• the molded article of the present invention contains the resin composition of the present invention.
• the molded article of the present invention can be obtained by shaping the resin composition of the present invention into a desired shape by a known molding method. Examples of molding methods include extrusion molding, injection molding, compression molding, blow molding, cast molding, lamination molding, lamination molding, and powder molding.
• the coating composition, adhesive composition or coating composition of the present invention contains an iminoctadine compound.
• the amount of the iminoctazine compound contained in the coating composition, adhesive composition or coating composition of the present invention can be appropriately set depending on the application.
• the coating composition, adhesive composition, or coating composition of the present invention contains, in addition to the iminoctadine compound, components that can be included in known coating compositions, adhesive compositions, or coating compositions (e.g., resins, solvents, , additives, etc.).
• the components can impart to the respective composition properties suitable for coatings, adhesives or paints. Properties include fluidity, adhesiveness, coatability, film-forming properties, lamination properties, blister resistance, adhesion, adhesiveness, sealing properties, decorative properties, and the like. Such characteristics can be realized by appropriately selecting the type and amount of resin to be used, the type and amount of solvent, the type and amount of additive, and the like.
• the liquid coating composition of the present invention is applied onto a substrate by a coating method such as brush coating, roll coating, bar coating, or spray coating, and then dried and, if necessary, cured.
• the substrate can be coated by
• the solid coating composition of the present invention can be placed on a substrate by dusting, sheeting, filming, or the like, and the substrate can be coated by pressing, fusing or adhering. .
• the antiviral agent composition, resin composition, coating composition, adhesive composition, or coating composition of the present invention can be used for various purposes.
• Synthetic resin paints include phenol resin paints, phthalate resin paints (e.g. alkyd resin paints), maleic acid resin paints, urea resin paints, melamine resin paints, vinyl resin paints (e.g. vinyl acetate resin paints, vinyl chloride resin paints). paint, styrene resin paint, acrylic acid resin paint, polyvinyl butyral resin paint, etc.), epoxy resin paint, silicone resin paint, furan resin paint, polyester resin paint, urethane resin paint, nitrocellulose resin paint, amino resin paint, fluorine resin paint etc. can be mentioned.
• Water-based paints include water-based paints, emulsion oil paints, emulsion polymerization paints (for example, vinyl acetate resin emulsion polymerization paints, vinylidene chloride vinyl chloride copolymer emulsion polymerization paints, acrylic acid resin emulsion polymerization paints, styrene resin emulsion polymerization paints, synthetic rubber latex paint, etc.).
• emulsion oil paints for example, vinyl acetate resin emulsion polymerization paints, vinylidene chloride vinyl chloride copolymer emulsion polymerization paints, acrylic acid resin emulsion polymerization paints, styrene resin emulsion polymerization paints, synthetic rubber latex paint, etc.
• the resin composition, coating composition, or coating composition of the present invention can further contain a coupling agent.
• a coupling agent is a compound that bonds materials with different properties, mainly inorganic and organic materials.
• Examples of coupling agents include silane coupling agents, titanate coupling agents, aluminate coupling agents, and zirconate coupling agents.
• Silane coupling agents include 2-(3,4-epoxycyclohexyl)ethyltrimethoxysilane, 3-glycidoxypropylmethyldimethoxysilane, 3-glycidoxypropyltrimethoxysilane, 3-glycidoxypropylmethyldimethoxysilane.
• ethoxysilane 3-glycidoxypropyltriethoxysilane, 3-methacryloxypropylmethyldimethoxysilane, 3-methacryloxypropyltrimethoxysilane, 3-methacryloxypropylmethyldiethoxysilane, 3-methacryloxypropyltriethoxysilane, etc. can be mentioned.
• Titanate-based coupling agents include titanium alkoxides such as tetraisopropyl titanate, tetra-n-butyl titanate, tetrakis(2-ethylhexyloxy)titanium, titanium-i-propoxyoctylene glycolate; titanium acetylacetonate, titanium tetraacetyl Acetonate, di-i-propoxy bis(acetylacetonato)titanium, di-n-propoxy bis(acetylacetonato)titanium, di-n-butoxy bis(acetylacetonato)titanium, diethoxy bis(acetyl acetonate), titanium complexes such as propanedioxytitanium bis(ethylacetoacetate), and the like.
• titanium alkoxides such as tetraisopropyl titanate, tetra-n-butyl titanate, tetrakis(2-
• aluminate-based coupling agents include aluminum alcoholates such as aluminum isopropylate, mono-sec-butoxyaluminum diisopropylate, and aluminum ethylate; ethylacetoacetate aluminum diisopropylate, aluminum bisethylacetoacetate/monoacetyl Acetonate, aluminum tris (ethylacetoacetate), aluminum tris (acetylacetonate), diethoxy mono (acetylacetonate) aluminum, di-i-propoxy mono (acetylacetonate) aluminum, di-n-propoxy mono (acetylacetonate) ) aluminum, di-n-butoxymono(acetylacetonato)aluminum, ethoxybis(acetylacetonato)aluminum, i-propoxybis(acetylacetonato)aluminum, n-propoxybis(acetylacetonato)aluminum, n-butoxybis
• Zirconate-based coupling agents include zirconium tetrakis (acetylacetonate), di-n-butoxybis (acetylacetonate) zirconium, zirconium tetrakis (ethylacetoacetate), diethoxybis acetylacetonate zirconium, and di-i-propoxybis.
• the resin composition, coating composition, or coating composition of the present invention may further contain a filler.
• Fillers include carbon black, graphene, carbon nanotube, glass fiber, iron oxide, barite, talc, calcium carbonate, kaolin, clay, silica, titanium dioxide, alumina, zirconia, silicone resin fine particles, fluororesin fine particles, acrylic resin fine particles, Examples include urethane-based resin fine particles, silicone-modified urethane-based resin fine particles, polyethylene fine particles, and polycarbonate-based resin fine particles.
• the laminate of the present invention comprises a substrate and a layer of the resin composition, coating composition, adhesive composition or coating composition of the present invention laminated thereon.
• Substrates that can be used in the present invention are not particularly limited. Examples of base materials include buildings in general, building materials, metals, rubbers, wood materials, plastic products, fibers, cloth, paper, ceramics, concrete, blocks, and bricks.
• a layer composed of the resin composition, coating composition, adhesive composition, or coating composition of the present invention does not impair the appearance because the color tone does not easily change over time, and exhibits excellent antiviral properties.
• Lamination on the substrate can be performed by a known method. For example, multicolor extrusion molding, coated extrusion molding, adhesion, fusion bonding, coating, spraying, powder molding, in-mold molding, film insert molding and the like can be mentioned.
• Example 1 82.73 parts by mass of ethylene glycol mono-n-butyl ether, 8.74 parts by mass of a silane coupling agent (3-methacryloxypropyltrimethoxysilane), organosilica sol (amorphous silica 30%, N-methyl-2-pyrrolidone 70% ) 3.5 parts by mass, aluminum (III) acetylacetonate 1.5 parts by mass, and 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• a silane coupling agent 3-methacryloxypropyltrimethoxysilane
• organosilica sol amorphous silica 30%, N-methyl-2-pyrrolidone 70%
• aluminum (III) acetylacetonate 1.5 parts by mass
• 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• composition A was applied to one side of a polyethylene terephthalate film (Lumirror (R) film (T60 transparent) 250 ⁇ m) of 148 mm ⁇ 210 mm using an automatic coating device (PI-1210: manufactured by Tester Sangyo Co., Ltd.). . After that, it was placed in a constant temperature bath at 100° C. and dried for 20 minutes. Next, the dried coating film was cured using an ultraviolet curing light source device (manufactured by Eyegraphics Co., Ltd.) to obtain a laminate in which a polyethylene terephthalate film and a film composed of non-volatile components of composition A were laminated.
• PI-1210 manufactured by Tester Sangyo Co., Ltd.
• the infectivity titer U was calculated in the same manner as above. From the calculated infectious titer T and infectious titer U, the antiviral activity value was calculated.
• the antiviral activity value is a value defined by the following formula.
• Antiviral activity value Log (infectious value U) - Log (infectious value T) The antiviral activity value against bacteriophage Q ⁇ was 4.8.
• the antiviral activity value was calculated in the same manner as described above, except that the bacteriophage ⁇ 6-containing solution was used instead of the bacteriophage Q ⁇ -containing solution, and the Pseudomonas syringae culture solution was used instead of the E. coli culture solution.
• the antiviral activity value against bacteriophage ⁇ 6 was 5.2.
• Example 2 83.56 parts by mass of ethylene glycol mono-n-butyl ether, 8.74 parts by mass of a silane coupling agent (3-methacryloxypropyltrimethoxysilane), organosilica sol (amorphous silica 30%, N-methyl-2-pyrrolidone 70% ) 3.5 parts by mass, aluminum (III) acetylacetonate 1.5 parts by mass, and 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• a silane coupling agent 3-methacryloxypropyltrimethoxysilane
• organosilica sol amorphous silica 30%, N-methyl-2-pyrrolidone 70%
• aluminum (III) acetylacetonate 1.5 parts by mass
• 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• Example 3 85.23 parts by mass of ethylene glycol mono-n-butyl ether, 8.74 parts by mass of a silane coupling agent (3-methacryloxypropyltrimethoxysilane), organosilica sol (amorphous silica 30%, N-methyl-2-pyrrolidone 70% ) 3.5 parts by mass, aluminum (III) acetylacetonate 1.5 parts by mass, and 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• a silane coupling agent 3-methacryloxypropyltrimethoxysilane
• organosilica sol amorphous silica 30%, N-methyl-2-pyrrolidone 70%
• aluminum (III) acetylacetonate 1.5 parts by mass
• 2-methyl-1-[4-(methylthio)phenyl]-2-morpholinopropan-1-one 0.2 parts by mass added and dissolved.
• composition D was applied to one side of a polyethylene terephthalate film (Lumirror (R) film (T60 transparent) 250 ⁇ m) of 148 mm ⁇ 210 mm using an automatic coating device (PI-1210: manufactured by Tester Sangyo Co., Ltd.). . After that, it was placed in a constant temperature bath at 100° C. and dried for 1 minute to obtain a laminate in which a polyethylene terephthalate film and a film composed of non-volatile components of composition D were laminated.
• Antiviral evaluation was performed using bacteriophage ⁇ 6. The antiviral activity value against bacteriophage ⁇ 6 was 5.2.
• composition E 5.0 parts by mass of a polyhexamethylene biguanide preparation (containing 20% polyhexamethylene biguanide) (1 part as polyhexamethylene biguanide) was added and mixed to obtain a liquid composition E.
• a laminate was obtained in the same manner as in Example 1, except that composition A was changed to composition E.
• Antiviral evaluation using bacteriophage Q ⁇ was performed.
• the antiviral activity value against bacteriophage Q ⁇ was 2.0.
• composition containing polyhexamethylene biguanide and resin has extremely low antiviral properties, but the composition of the present invention (Example) has good antiviral properties.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dentistry (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Polymers & Plastics (AREA)
• Agronomy & Crop Science (AREA)
• General Chemical & Material Sciences (AREA)
• Toxicology (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (2)

Publications (1)

Family

ID=87883535

Family Applications (1)

Country Status (3)

Citations (7)

• 2023
  • 2023-02-21 JP JP2024504632A patent/JPWO2023167055A1/ja active Pending
  • 2023-02-21 WO PCT/JP2023/006177 patent/WO2023167055A1/ja not_active Ceased
  • 2023-02-23 TW TW112106775A patent/TW202346482A/zh unknown

Patent Citations (7)

Also Published As

Similar Documents

Legal Events